{"resolution": {"@star-print": "no-star-print", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "@display": "yes", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. RES. 161"}, "official-title": {"#tail": "\n\t", "@display": "yes", "#text": "Expressing the sense of the House of\n\t\t  Representatives that the Food and Drug Administration should encourage the use\n\t\t  of abuse-deterrent formulations of drugs."}, "session": {"#tail": "\n\t\t", "@display": "yes", "#text": "1st Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "IV"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20130415", "#text": "April 15, 2013"}, "#tail": "\n\t\t", "@display": "yes", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and\n\t\t\t Commerce"}, "sponsor": {"#tail": " (for himself, ", "#text": "Mr. Rogers of\n\t\t\t Kentucky", "@name-id": "R000395"}, "cosponsor": [{"#tail": ", ", "#text": "Mr.\n\t\t\t Keating", "@name-id": "K000375"}, {"#tail": ",\n\t\t\t ", "#text": "Mr. Wolf", "@name-id": "W000672"}, {"#tail": ",\n\t\t\t ", "#text": "Mr. Rahall", "@name-id": "R000011"}, {"#tail": ",\n\t\t\t ", "#text": "Mr. Grimm", "@name-id": "G000569"}, {"#tail": ",\n\t\t\t ", "#text": "Mr. Lynch", "@name-id": "L000562"}, {"#tail": ", and\n\t\t\t ", "#text": "Mr. Tierney", "@name-id": "T000266"}, {"#tail": ") submitted the following\n\t\t\t resolution; which was referred to the ", "#text": "Mr. Aderholt", "@name-id": "A000055"}]}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "RESOLUTION"}}, "@resolution-stage": "Introduced-in-House", "@resolution-type": "house-resolution", "resolution-body": {"#tail": "\n", "@style": "traditional", "section": {"@section-type": "undesignated-section", "#tail": "\n  ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " that the ", "@entity-type": "federal-body", "#text": "House of\n\t\t\t Representatives", "@entity-id": "0050"}, {"#tail": " should exercise its\n\t\t\t acknowledged authority to\u2014", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "That it is the sense of the "}, "enum": {"#tail": "\n      "}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "refuse to approve\n\t\t\t generic versions of non-abuse-deterrent opioid products that have been replaced\n\t\t\t in the market with abuse-deterrent formulations; and"}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "HEA3D222B07474BF5B042F57907A80D95", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "require generic\n\t\t\t versions of abuse-deterrent opioid products to be formulated with comparable\n\t\t\t abuse-deterrent features."}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "H596261FDCB6545F99FAE28830DF20CAC", "#text": "\n        "}], "@display-inline": "yes-display-inline", "#text": "\n      ", "@id": "HCD89C54105B741709347FB2FF441295B"}, "#text": "\n\t\t", "@id": "H2DE0AC357441414DBB2533926F9A8FC9"}, "@key": "H", "@dms-id": "HD087D001E6DD4B0AB713AE943B722049", "@public-private": "public", "#text": "\n\t", "preamble": {"#tail": "\n\t", "whereas": [{"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the approval and marketing of generic versions that do not have\n\t\t\t abuse-deterrent features are likely to prevent achievement of the public health\n\t\t\t purposes of the efforts to develop such abuse-deterrent formulations;", "@entity-type": "federal-body", "#text": "Food and Drug\n\t\t\t Administration,", "@entity-id": "7524"}, "#text": "Whereas when abuse-deterrent formulations of a drug have\n\t\t\t been developed, approved, and recognized as effective by the "}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and the\n\t\t\t ", "@entity-type": "federal-body", "#text": "Office of National Drug Control Policy", "@entity-id": "1127"}, {"#tail": " have for many years strongly encouraged\n\t\t\t manufacturers of opioid drug products to develop abuse-deterrent formulations\n\t\t\t designed to prevent or discourage the abuse or misuse of those products;", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Whereas the "}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas in response, several opioid drug manufacturers\n\t\t\t have developed abuse-deterrent formulations;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "#text": "Whereas helping to reduce the level of abuse of opioid\n\t\t\t drug products is dependent on the widespread adoption of new technologies and\n\t\t\t approaches to the safer formulation of these drugs;"}, "#text": "\n      "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " has\n\t\t\t acknowledged that the ", "@entity-type": "federal-body", "#text": "Commissioner of Food and Drugs", "@entity-id": "7524"}, {"#tail": " has the authority under\n\t\t\t current law to require generic versions of products that have been formulated\n\t\t\t or reformulated with abuse-deterrent features to have comparable features;\n\t\t\t and", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}], "#text": "Whereas the "}, "#text": "\n      "}, {"#tail": "\n  ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", which would similarly promote abuse-deterrent technologies in addictive\n\t\t\t painkillers: Now, therefore, be it", "@entity-type": "act", "#text": "Stop Tampering with Prescription Pills (STOPP)\n\t\t\t Act", "@value": "Stop Tampering with Prescription Pills (STOPP) Act"}, "#text": "Whereas fourteen Members of Congress in a bipartisan\n\t\t\t coalition have cosponsored the "}, "#text": "\n      "}], "#text": "\n\t\t"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-04-15"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HRES 161 IH: Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs."}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}